Effects of Inosine on Glycolysis and Contracture During Myocardial Ischemia E. Douglas Lewandowski, Donald L. Johnston, and Robert Roberts
The effects of inosine (INO) on substrate metabolism and rigor formation in ischemic myocardium were examined in isolated rabbit hearts. Metabolite content was assessed in tissue extracts by chemical analysis and in the whole heart by`C and 31P nuclear magnetic resonance spectroscopy. In ischemic hearts metabolizing either or [1-13C glucose, 1 mM INO increased both total and D3C-labeled alanine content; lactate content was unaffected. At 3 minutes of ischemia, tissue alanine was 1.81±0.11 ,uM/g wet wt (mean+SEM) in hearts perfused with pyruvate+INO versus 1.23 ±0.15 ,M/g wet wt in hearts perfused with pyruvate alone (p<0.05). INO reduced tissue glycogen during ischemia in pyruvate-perfused hearts. Tissue alanine content in ischemic hearts that were supplied glucose+INO (1.29±0.13 ,M/g wet wt) was greater than in ischemic hearts supplied glucose alone (0.65 ±0.14 ,M/g wet wt). Alanine was found to originate from pyruvate and was a glycolytic end product in glucoseperfused hearts. INO raised the [3-13C] possibly at the expense of glycogen. Supplemental glucose improved the effectiveness of INO with pyruvate to preserve ATP (pyruvate+glucose=42+--6%; pyruvate+glucose+INO=72+--6%) and further delayed rigor (pyruvate+glucose=13.3+1.5 minutes; pyruvate+glucose+INO= 20.3±+1.8 minutes). Glucose metabolism supported improved energetic and contractile states in ischemic hearts treated with INO. Thus, cardioprotection of the ischemic heart by INO was associated with preservation of functional integrity and improved energy production due to increased glycolytic activity. Activation of glycolysis in the presence of INO was accommodated by augmented alanine production without the additional accumulation of lactate. (Circulation Research 1991;68:578-587) I nosine has been used clinically to improve left ventricular function' but has an ill-defined role in benefiting stressed myocardium. As a supplemental agent, inosine has been noted to improve high-energy phosphate content in ischemic and reperfused myocardium.2,3 Inosine is a naturally occurring adenine nucleoside in myocardial metabolism. A product of adenosine deamination in the heart, inosine represents the catabolism of adenine nucleotides in ischemic myocardium. Total tissue purine nucleosides and nucleobases increase because of high-energy phosphate depletion during ischemia, and inosine represents the highest fraction of total accumulated purines within the ischemic myocardium. 4 The significant fraction of purines that accumulates in the form of inosine is slowly metabolized to hypoxanthine and xanthine by the vascular endothelium and is eventually washed out along with other metabolites during reperfusion.
A previous report5 suggests that washout of the accumulated purines on reperfusion impairs regeneration of the adenine nucleotide pool and thereby limits the energy store available to support normal levels of contractility. Supplementation of reperfusion media with nucleotide precursors, to counteract purine washout, has been shown to aid the metabolic recovery of reperfused hearts. 6 Supplemental inosine has been shown to improve both the functional and metabolic state of myocardium during ischemia in the in vivo canine heart7 and has been shown to reduce infarct size of the canine heart after coronary artery occlusion. 8 Whether the observed improvements in compromised myocardium treated with inosine result from metabolic effects is not clearly established, since this purine exerts both vasodilatory9 and inotropic10 effects. But inosine has been shown to enhance the viability of cultured myocytes during simulated ischemia by a mechanism that is apparently distinct from the known vasoactive properties of this nucleoside.11 A study by Harmsen et a12 has shown that incorporation of exogenous inosine into the ATP pool did not account for an observed increase in ATP during reperfusion with inosine. This finding suggests an additional role for inosine other than in providing nucleotide precursor molecules. More recent findings3 demonstrate that pretreating myocardium with inosine reduces ATP loss during subsequent ischemia, before reperfusion is allowed and precursor washout becomes a limiting factor. Therefore, inosine may aid ischemic myocardium by either reducing ATP loss, possibly by reducing nucleotide degradation through bulk effects, or by improving ATP synthesis apart from simply counteracting purine turnover. The action of inosine to enhance tissue ATP during ischemia suggests a metabolic influence on the preservation of myocardium, since the relation between energy metabolism and ischemic damage is well documented.12,13 Therefore, the potential for inosine to improve energy production through a nonanabolic role is an area to be investigated with respect to the physiological changes occurring within ischemic myocardium.
In the present study, we attempted to determine whether inosine enhances ATP synthesis by increasing anaerobic substrate metabolism in ischemic myocardium. Since glucose has been found to be an effective substrate in delaying ischemic contracture as compared with non-glycolytic substrates,14 the substrate-dependent effects of inosine on ischemic contracture were also investigated. These experiments were designed to observe the metabolism of the carbon-based substrates, glucose and pyruvate, and to use these agents as markers of glycolytic activity during ischemia. The production of the glycolytic end products, lactate and alanine,15 highenergy phosphate content, and the development of ischemic contracture were all examined in isolated rabbit hearts treated with exogenous inosine. The use of 13C and 31P nuclear magnetic resonance (NMR) spectroscopy facilitated collection of metabolic data from intact hearts during normal perfusion and throughout the development of ischemic contracture. Our findings suggest that 1) stimulating glycolytic alanine production, without increasing the accumulation of inhibitory lactate, contributes favorably to energy metabolism in the ischemic heart, 2) inosine treatment affects the relative activities of alanine transaminase and lactate dehydrogenase during pyruvate metabolism, and 3) adenine nucleotide breakdown and intermediary metabolism may be linked via tissue nucleoside levels.
Materials and Methods Heart Preparation
Male Dutch-Belted rabbits (550-750 g) were heparinized (2,500 IU) and anesthetized with pentobarbital sodium (100 mg/kg i.p.). The heart was rapidly excised and washed in cold (0°C) isotonic KCI solution for cardioplegia. Hearts were perfused in retrograde fashion initially with a modified Krebs-Henseleit buffer containing (mM) NaCl 116, KCl 4, CaCl2 1.5, MgSo4 1.2, NaH2PO4 1.2, NaHCO3 25, and glucose 5 and were gassed with 95% 02-5% CO2 at 37°C at a constant pressure of 100 cm H20. A latex balloon, connected to a water-filled hydrostatic line and pressure transducer, was fitted into the left ventricle via the left atrium. The balloon was inflated with water to a diastolic pressure of 5-10 mm Hg within the left ventricle. Left ventricular developed pressure was recorded from the transducer onto a physiological monitoring system (Gould, Inc., Cleveland, Ohio).
Perfusion Protocols
Tissue sampling. The heart preparation was placed inside a water-jacketed glass vial to maintain temperature at 37°C. Hearts were initially sustained with glucose-containing medium (circulated 2-1 reservoir) until hemodynamics were stabilized (10 minutes). The perfusate supply was then switched to a 400-ml reservoir of similar buffer containing 99% 13C-en- Hearts received these substrates either with or without 1 mM inosine. After 15 minutes of perfusion with 3C-enriched media, hearts were rapidly frozen with aluminum clamps cooled in liquid nitrogen. Other hearts receiving 13 C-enriched substrates for 15 minutes were subjected to a brief (3-minute) period of zero-flow ischemia before freezing. The number of individual hearts in each group is shown in Table 1 . The 3-minute period of ischemia was selected to correspond to the first time-averaged 13C NMR spectrum (0-6 minutes of ischemia) collected from intact ischemic hearts. Therefore, the effects of inosine treatment on intermediary metabolite levels could be compared between tissue assay and 13C NMR of intact hearts.
Intact heart studies. The heart preparation was placed inside a 20-mm glass vial, which was then situated within the NMR system (see "NMR Measurements" below). Sample temperature was maintained at 37°C by warm air flow controlled at the NMR system console. Hearts were sustained with the initial, glucose-containing medium (2 1) until the NMR spectrometer was set for data acquisition (10 minutes 
Tissue Biochemistry
Perchloric acid extractions were performed on frozen ventricle tissue, as previously described. 16 Tissue glycogen and lactate determinations were performed by ultraviolet spectrophotometric analysis (Ultrospec II, LKB Biochrom Ltd.) from the methods described by Bartley and Dean17 and Henry,'8 respectively. Proton NMR spectroscopy was performed on extract material that was lyophilized and reconstituted (50 mg/ml) in deuterium oxide (MSD Isotopes). Tissue alanine was determined from the proton NMR signal arising from the methyl group of alanine relative to that of the known methyl group proton concentration from lactate assays. Proton NMR pulsing conditions are described below (see "NMR Measurements"). The ratio of alanine to lactate derived from exogenous, 13C-enriched substrates was determined from 13C NMR spectroscopy of reconstituted extract under the pulsing conditions described below.
NMR Measurements
All NMR data were acquired on a spectrometer (AM 400, Bruker Instruments, Inc., Billerica, Mass.) equipped with an Aspect 3000 series computer and a 9.4-T, vertical-bore superconducting magnet. Relative metabolite levels within each spectrum were determined by integration of the areas under each resonance peak of interest using an analysis subroutine within the NMR dedicated software (Bruker Instruments).
Spectra from isolated hearts were acquired with a 20-mm radiofrequency probe (Bruker Instruments) tuned to both the 31p (161 MHz) and 13C (100.6 MHz) frequencies. Magnetic field homogeneity was adjusted for each heart by observing the proton signal from water through the separate proton-decoupling coil. Homogeneity was adjusted to give a proton line width of [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Hz. Alternating 13C and 31p spectra were obtained from isolated hearts throughout the perfusion and ischemia protocol. Acquisition of the 13C signal was performed over 6-minute time blocks (450 pulse angle, 2-second recycling time) with minimal saturation of observed resonances.1920 Bilevel broadband decoupling was used to eliminate carbon-proton couplings (0.5 W at delay and 6 W at pulse to avoid sample heating). A natural abundance "C spectrum was obtained from each heart before "C enrichment. The background "C signal was then digitally subtracted from subsequent spectra obtained during enrichment. The signal was processed by doubling the data points to improve digital resolution and by exponential filtering (18) (19) (20) (21) (22) (23) (24) (25) to enhance the signal-tonoise ratio. Data was converted to the frequency domain using Fourier transformation.`p spectra of isolated hearts were acquired over 1-minute time blocks (450 pulse, 2.1-second recycling time). Raw data were filtered (12 Hz) to improve the signal-tonoise ratio, and Fourier transformation was then performed. Peak assignments within spectra were determined relative to phosphocreatine at 0 ppm, and ATP levels were determined from the ,3-phosphate peak. Tissue pH was determined from 31P spectra as previously described. 21 Spectra from tissue extracts were acquired with a 5-mm`C/MH probe (Bruker Instruments). Field homogeneity was adjusted using the proton and deuterium signals. Samples were spun at 20 Hz to reduce local field inhomogeneities and improve signal resolution. Proton spectra were collected over 15-30 minutes (450 pulse, 4-second recycling time). The signal intensity ratio of the methyl group protons of alanine (1.49 ppm) to that of lactate (1.35 ppm) was not affected by varying the interpulse delay, confirming similar relaxation effects at both resonances. Within each proton spectrum, "3C-labeled metabolites were distinguished from the unlabeled fraction by the apparent methyl proton signals that were split by J-coupling to 13C. 22 The presence of 13C in the methyl groups of alanine and lactate resulted in a 124-Hz splitting of the proton signals that then flanked the central, unsplit signal of the methyl protons bound to 12C.
13C spectra of extracts were collected overnight (450 pulse, 2-second recycling time) using continuous broadband proton decoupling. Exponential filtering (2) (3) (4) Hz) was applied before Fourier transformation. The effects of relaxation differences on the 13C signal from the methyl groups of alanine and lactate were taken into account by prolonging the interpulse delay (10 seconds). Effects of nuclear Overhauser enhancement differences on the alanine-to-lactate 13C signal ratio were accounted for by data collection with and without nuclear Overhauser enhancement contributions.23
Statistical Analysis
Within-group differences were examined using analysis of variance. Comparisons between groups were analyzed using Student's unpaired two-tailed t test. Differences in mean values were assessed using a significance level of 5% (p<0.05). Data is presented as mean±+-SEM. Results Carbon-based substrates were metabolized by the perfused heart as shown in the simplified metabolic flow chart in Figure 1 . Glucose and pyruvate were either oxidized via subsequent entry of the carbon [1- skeletons derived from these substrates into the tricarboxylic acid cycle or metabolized via nonoxidative formation of either lactate or alanine. During ischemic conditions, when the oxidative route was unavailable, anaerobic metabolism of glucose and pyruvate resulted in increased tissue lactate and alanine levels. The ratio of alanine to lactate content in the myocardium indicated the activity of the alanine transaminase enzyme relative to that of the lactate dehydrogenase enzyme, as shown in Figure 1 . Use of`3C-enriched substrates facilitated the direct observation of such metabolism with NMR spectroscopy as the`3C label was incorporated into the C-3 methyl groups of both lactate and alanine. (Table 1 ). In contrast, inosine treatment raised tissue alanine content in three of four groups of hearts: 1) glucose-perfused hearts (81%), 2) glucose-perfused ischemic hearts (98%), and 3) pyruvate-perfused ischemic hearts (47%). The effect of supplemental inosine on tissue alanine levels is illustrated in Figure 4 . Only during normal perfusion with pyruvate was alanine content of the heart presence of exogenous inosine resulted in a mean tissue glycogen level that was 35% lower than that observed during control perfusion with pyruvate. None of the other groups displayed significant differences in glycogen levels after inosine treatment.
13C NMR Analysis of Intact, Perfused Hearts
Relative levels of 13C-enriched alanine and lactate were observed within 13C spectra from isolated rabbit A.
[3 13C] ALA hearts with an alternating collection of 31p spectra to assess potential changes in high-energy phosphates. Representative changes in the relative levels of lactate and alanine produced from [3-13C] pyruvate metabolism upon switching from normal perfusion to ischemia are illustrated in the expanded regions of the 13C spectra displayed in Figure 5 . As shown, conversion of [3-13C] Figure 6 for each experimental group. The ALA: LAC ratio was used as a measure of the relative flux through the enzymes, alanine transaminase versus lactate dehydrogenase, throughout each protocol. No lactate signal was observed before ischemia. Perfusion of hearts with [3-13C] pyruvate alone or in combination with unlabeled glucose allowed the action of these two enzymes on pyruvate to be assessed, without rate contributions from other glycolytic enzymes. At 0-6 minutes of ischemia, hearts loaded with [3- (Figure 6 ). Thus, additional inosine promoted an increase in alanine transaminase activity relative to lactate dehydrogenase during early ischemia. This increase in transaminase activity accommodated an increase in glycolytic flux, as demonstrated by increased end-product accumulation during ischemia (Table 1 and Figure 6 ). The increase in ALA: LAC produced by inosine was not sustained for longer than the 6 minutes of ischemia. At 8-14 minutes, ALA: LAC was not found to be different between treated and untreated hearts, because, after the 0-6-minute observation, the lactate signal continued to rise while the signal from alanine was reduced.
A.
PCr 31p NMR Data
31P spectra demonstrating the changes in highenergy phosphate content during the course of a single experiment with pyruvate perfusion are shown in Figure 7 . During ischemia, phosphocreatine was depleted to undetectable levels, and tissue ATP was reduced within 7 minutes. Inorganic phosphate content rose progressively with the duration of ischemia, and the resonance peak shifted to the right as tissue pH fell.
Inosine treatment did not elicit any change in high-energy phosphates during normal perfusion but did result in increased ATP content at 7 minutes of ischemia within hearts supplied with glucose. Also, tissue pH was unaffected by inosine treatment both at normal perfusion (pH 7.1) and during ischemia, when pH levels fell to a range of 6.02-6.49 at 7 minutes. Figure 8 illustrates ATP levels during ischemia for each of the experimental groups. The reduction in ATP was consistent with previous reports in both rabbit3 and rat26 heart. Exogenous inosine was effective in preserving ATP levels at ischemia only when glucose was available. The addition of pyruvate did not affect tissue ATP levels at ischemia when supplemental glucose was provided. However, pyruvate alone was not sufficient to maintain heightened ATP levels during ischemia in the presence of exogenous inosine. The data suggest that the enhanced ATP levels afforded by inosine treatment were derived from anaerobic glycolysis, a mode of energy production not supported by pyruvate.
Ischemic Contracture
The time course of increasing diastolic pressure during ischemia, indicative of contracture, was significantly shorter in hearts perfused with pyruvate than with supplemental glucose or glucose alone ( Figure  9 ). Thus, both the onset of contracture and complete rigor (i.e., stone heart)27 occurred earliest among B.
P. Total tissue alanine (labeled and unlabeled) increased during ischemia with inosine treatment, and the unlabeled alanine is likely to reflect glycolytic metabolism of endogenous substrates (i.e., glycogen). The reduced glycogen levels within inosine-treated, pyruvate-perfused hearts during ischemia suggest that the unlabeled lactate and alanine did indeed originate from endogenous glycogen stores. This reduction of glycogen presumably occurred to support the observed increase in glycolytic end-product formation with inosine. Therefore, we have assumed that unlabeled products of glycolysis detected within the ischemic myocardium preperfused with [3-13C] pyruvate reflect the extent of anaerobic glycolysis.
As calculated from metabolite levels within hearts receiving [3-13C] pyruvate, the average amount of ATP generated by the conversion of the unlabeled glycogen to alanine and lactate within 3 minutes of ischemia was 4.42 ,uM in inosine-treated hearts as compared with 4.09 ,uM in the untreated hearts. Similar calculations in the glucose-perfused hearts indicated average ATP production from glycolysis during 3 minutes of ischemia to be 4.30 ,tM in inosine-treated hearts versus 3.60 ,uM in untreated hearts. A comparison of glycogen versus glucose as metabolic fuels for anaerobic ATP production is beyond the scope of this study. However, the difference in pyruvate versus glucose in delaying contracture presents an interesting paradox with regard to these estimates of ATP production during early ischemia. Nevertheless, indirect estimation of glycolytic ATP supports our hypothesis of increased an-aerobic energy production with inosine treatment. Whether the observed increases in glycolytic endproduct formation are sufficient to account for the difference in ATP content as observed within intact hearts with 31P NMR cannot be determined from these data. Conversion of inosine plus aspartate (from glutamate and oxaloacetate) to adenylosuccinate cannot be ruled out as an additional source of AMP in inosine-treated myocardium. Also, the observations do not eliminate the possibility of residual oxidative phosphorylation during very early ischemia,28 which may contribute to greater energy production than is available from glycolysis alone. Such oxidative activity may then also provide the additional NAD+ required to support the observed increase in glycolysis.
The observation that one 13C NMR signal from lactate and alanine increased during ischemia in the [1-13C]glucose-perfused heart is consistent with our findings in the freeze-clamped hearts. Our findings are also consistent with a previous report by Taegtmeyer et al15 showing tissue alanine to appear in significant amounts as an end product of glycolysis. The ratio of "C-enriched alanine to lactate was not elevated in inosine-treated hearts when assessed later in the ischemic period, demonstrating that the effect on alanine production was not sustained throughout the course of contracture development. The time course of the inosine effect on alanine production is likely a function of the tissue redox state, which would favor lactate production as the pool of glutamate was reduced, NADH continually increased, and glycolysis slowed.
That inosine treatment increased the alanine to lactate content in myocardium as detected by`3C NMR demonstrates that this naturally occurring purine nucleoside, in high concentration, induces higher activities of alanine transaminase without affecting lactate production. But the mechanism for this enzyme activation in the presence of exogenous inosine is not apparent from these experiments. Maximal activity of lactate dehydrogenase during ischemia29 may represent the upper limit of glycolytic end-product synthesis by this route. Regulation of the dehydrogenase via tissue redox state or feedback inhibition by accumulated lactate may not accommodate a further increase in glycolytic rate. Increased alanine transaminase flux may simply accommodate an undetermined mechanism for increased glycolytic activity. Therefore, the observed increase in alanine production may be a substrate-dependent reaction reliant on glycolytic pyruvate production and tissue glutamate levels.
Both the metabolic and physiological (contracture) effects of inosine treatment occurred independent of tissue pH, since pH was reduced similarly in all groups during ischemia. The addition of glucose to pyruvate was required for improving ATP content in the ischemic heart with inosine. These data suggest that the effects of inosine on ATP content are at least partially dependent on glycolysis as fueled by glucose.
Nevertheless, the ATP content observed with`P NMR at 7 minutes of ischemia was consistent with previously reported ATP levels of 7 minutes of ischemia with and without inosine treatment. 3 The consistency of these data suggests that ATP levels within the current experimental groups were also similar to previously reported levels at 2 minutes of ischemia, when inosine was already found to be effective.3 Thus, tissue metabolite concentrations from hearts frozen at 3 minutes of ischemia were assessed within the time frame of a previously demonstrated effect of inosine on ATP content.
The data regarding substrate effects of ischemic contracture are consistent with an earlier report by Bricknell et al14 demonstrating the effectiveness of glycolytic ATP in the prolongation of contracture times. Our data show that addition of glucose to pyruvate resulted in an additive delay in contracture in response to inosine. Thus, inosine was more effective in prolonging contracture time when exogenous glycolytic substrate was provided. Pyruvate contributed to a significant amount of lactate that was not generated from glycolysis and did not support glycolytic ATP production. Additional glycolytic "protection" from contracture with glucose alone was not in evidence with inosine treatment except during prolonged ischemia (rigor), since glycolysis was likely to be already stimulated by the exogenous glucose. 28 The delay in the onset of contracture and maximal contracture afforded by inosine treatment was evidence of the protective effect of this purine nucleoside on the ischemic myocardium. Owen et a128 have demonstrated that glucose flux rate is important in determining the onset of contracture. In the same study, the authors have shown the glucose concentration to be a determining factor in the progression of contracture. Thus, even a brief period of accelerated glycolytic ATP production without the inhibitory effects of additional lactate accumulation may suffice to delay rigor formation in ischemic myocardium, as may have been the case after inosine treatment. Our finding that the purine nucleoside, inosine, affects glycolysis is not without precedent. Recently, Wyatt et al31 demonstrated the ability of adenosine to stimulate glycolytic flux in isolated rat hearts via an A,-receptormediated response. Although vasoactive properties of inosine have been shown to occur independent of the adenosine receptors,9 the metabolic effects of this nucleoside are only recently realized, and receptor involvement is not characterized.
Although the effectiveness of inosine to preserve ATP appears dependent on glycolysis, the means of regenerating NAD+ to support increased glycolytic flux in the presence of inosine is not apparent from these data. Since glutamate is a reactant in the conversion of we have demonstrated increased production of glycolytic end-product formation within inosine-treated ischemic hearts with improved effectiveness of inosine in the presence of glucose, these results suggest that further metabolic activity, in addition to glycolysis, is stimulated in response to inosine.
In summary, our finding that inosine treatment delayed rigor formation in the ischemic heart is consistent with previous studies demonstrating a cardioprotective role for inosine. The current study, however, demonstrates that inosine exerts an effect on myocardial intermediary metabolism and thereby contributes to improving the energy status of the heart under stress. The additive effects of glucose to the ability of inosine administration in delaying rigor suggest an additional link between the metabolic effects of exogenous inosine and the preservation of myocyte function. The findings also demonstrate that naturally occurring products of purine metabolism can influence substrate metabolism and glycolytic end-product formation. Thus, this study demonstrates an additional link between adenine nucleotide catabolism and glycolysis and confirms a protective role for inosine in the ischemic myocardium.
